









Markets
/
Stocks
/
nasdaq-dbvt
/

Dbv Technologies SA

DBVT

9.143USD

-0.017-0.18%

Close 09/29, 16:00（ET）Quotes delayed by 15 min

1.25BMarket Cap

LossP/E TTM



Dbv Technologies SA

9.143

-0.017-0.18%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Dbv Technologies SA

Currency: USD Updated: 2025-09-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dbv Technologies SA's Score

Industry at a Glance

Industry Ranking

98 / 174

Overall Ranking

275 / 4714

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Hold

Current Rating

20.570

Target Price

+124.56%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dbv Technologies SA Highlights

StrengthsRisks

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.15M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 18.33.

Fairly Valued

The company’s latest PE is -8.11, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.48M shares, decreasing 40.71% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 17.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-29

The company's current financial score is 7.45, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.47M, representing a year-over-year increase of 26.18%, while its net profit experienced a year-over-year increase of 26.45%.

Score

Industry at a Glance

Previous score

7.45

Change



Financials

8.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Dbv Technologies SA's Company Valuation

Currency: USD Updated: 2025-09-29

The company’s current valuation score is 6.51, which is lower than the Pharmaceuticals industry's average of 7.18. Its current P/E ratio is -8.11, which is -31.03% below the recent high of -5.59 and -26.87% above the recent low of -10.29.

Score

Industry at a Glance

Previous score

6.51

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 98/174

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-29

The company’s current earnings forecast score is 6.67, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Dbv Technologies SA is 20.00, with a high of 35.00 and a low of 7.28.

Score

Industry at a Glance

Previous score

6.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Hold

Current Rating

20.570

Target Price

+124.56%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Dbv Technologies SA

DBVT

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-29

The company’s current price momentum score is 6.61, which is lower than the Pharmaceuticals industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 10.20 and the support level at 8.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.53

Change

0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.107

Sell

RSI(14)

43.416

Neutral

STOCH(KDJ)(9,3,3)

19.108

Neutral

ATR(14)

0.451

High Vlolatility

CCI(14)

-101.816

Sell

Williams %R

82.474

Oversold

TRIX(12,20)

-0.092

Sell

StochRSI(14)

72.863

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

9.181

Sell

MA10

9.420

Sell

MA20

9.401

Sell

MA50

9.524

Sell

MA100

9.575

Sell

MA200

7.379

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-29

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.28. The latest institutional shareholding proportion is 1.81%, representing a quarter-over-quarter increase of 0.07%. The largest institutional shareholder is Steven Cohen, holding a total of 17.00K shares, representing 0.01% of shares outstanding, with 95.56% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

1.46M

Yiheng Capital Management, L.P.

656.31K

UBS Financial Services, Inc.

163.49K

+0.68%

Risk Assessment

Currency: USD Updated: 2025-09-29

The company’s current risk assessment score is 2.62, which is lower than the Pharmaceuticals industry's average of 5.10. The company's beta value is -0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.